Frontier Wealth Management’s TG Therapeutics TGTX Stock Holding History

Frontier Wealth Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-151,750	Closed	-$1.49M	–	368
2020 Q1	$1.49M	Sell	151,750 -45,000	-23%	-$568K	0.24%	95
2019 Q4	$2.18M	Sell	196,750 -30,000	-13%	-$228K	0.35%	67
2019 Q3	$1.27M	Buy	226,750 +20,000	+10%	+$139K	0.19%	111
2019 Q2	$1.79M	Buy	206,750 +45,000	+28%	+$340K	0.26%	81
2019 Q1	$1.3M	Buy	161,750 +131,750	+439%	+$712K	0.18%	127
2018 Q4	$123K	Hold	30,000	–	–	0.02%	338
2018 Q3	$168K	Buy	30,000 +5,000	+20%	+$57.1K	0.02%	368
2018 Q2	$329K	Sell	25,000 -5,000	-17%	-$68.8K	0.05%	280
2018 Q1	$426K	Buy	+30,000	New	+$383K	0.06%	246
2017 Q4	–	Sell	-50,000	Closed	-$593K	–	395
2017 Q3	$593K	Hold	50,000	–	–	0.09%	201
2017 Q2	$503K	Hold	50,000	–	–	0.08%	225
2017 Q1	$583K	Hold	50,000	–	–	0.09%	203
2016 Q4	$233K	Buy	50,000 +15,000	+43%	+$88K	0.04%	331
2016 Q3	$271K	Buy	+35,000	New	+$225K	0.04%	294

Other funds holding TGTX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Frontier Wealth Management's TGTX Position: Q2 2020 in Review

Frontier Wealth Management sold out of TG Therapeutics (TGTX) in Q2 2020, closing a stake of 151,750 shares — an estimated $1.49M sold.

Frontier Wealth Management first reported a position in TGTX in Q3 2016 and held it in 14 quarters. The position peaked at $2.18M in Q4 2019. 175 funds tracked by Wall St. Rank hold TGTX as of Q2 2020.

Frontier Wealth Management reported no remaining TG Therapeutics position as of Q2 2020 after selling out during the quarter.
Frontier Wealth Management sold 151,750 TG Therapeutics shares in Q2 2020, an estimated $1.49M.
Frontier Wealth Management first reported a position in TG Therapeutics in Q3 2016 and held it in 14 quarters.
Frontier Wealth Management's TG Therapeutics position peaked at $2.18M in Q4 2019.
175 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2020.

Based on Frontier Wealth Management's 13F filing for Q2 2020, filed 14 Aug 2020.